Drug Trial Radar · NCT05180708
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Last checked: Nov 20, 2026Latest source record: Aug 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
87
Actual
Start
Nov 29, 2021
Primary completion
Jun 30, 2023
Study completion Jun 30, 2023
Sponsor
- Lead sponsor
- Palvella Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the safety and efficacy of QTORIN 3.9% rapamycin anhydrous gel in the treatment of adults with Pachyonychia Congenita. This study includes a screening period, baseline period and 6-month treatment period.
Conditions
- Pachyonychia Congenita
Interventions
QTORIN 3.9% rapamycin anhydrous gelDrug
QTORIN 3.9% rapamycin anhydrous gel
VehicleDrug
Matching vehicle (QTORIN anyhydrous gel)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient Global Assessment of Activities Difficulty ScaleTime frame: 6 months
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Stanford University
Palo Alto, California
Yale University
New Haven, Connecticut
Park Avenue Dermatology
Orange Park, Florida
Minnesota Clinical Study Center
Fridley, Minnesota
Oregon Health and Sciences University
Portland, Oregon
DermResearch, Inc.
Austin, Texas
University of Utah
Murray, Utah
Royal London Hospital
London, Whitechapel, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.